What is the efficacy and safety of blinatumomab in managing young adults with high-risk B-cell acute lymphoblastic leukemia?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18408857
Cited by: 0

Abstract

Blinatumomab shows significant efficacy in improving survival outcomes compared to chemotherapy for young adults with high-risk B-cell acute lymphoblastic leukemia, with a manageable safety profile.

Fields of Study & Subjects

Acute Lymphoblastic Leukemia research CAR-T cell therapy research Lymphoma Diagnosis and Treatment

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
29 January 2026